Using ddPCR to Detect Mycoplasma Contamination

The accelerated pace of gene therapies is a sign of enhancements in our understanding of genetics and viral engineering as well as innovation in manufacturing processes. Despite this progress, gene therapy development is not a perfect science, and manufacturers must be careful to monitor the quality of their products before they reach patients. The sensitivity of droplet digital PCR (ddPCR) helps manufacturers detect Mycoplasma contamination in adeno-associated vector-based gene therapy products.

Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing May 2021 eBook.

About the author

Mark White, PhD, is associate director, Biopharma Product Marketing, at Bio-Rad Laboratories.

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing,May 2021
May 2021
Pages: 26–32

Citations

When referring to this article, please cite it as M. White, “Using ddPCR to Detect Mycoplasma Contamination," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).